Exact Mass: 496.2486

Exact Mass Matches: 496.2486

Found 500 metabolites which its exact mass value is equals to given mass value 496.2486, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Leukotriene D4

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-2-[(carboxymethyl)carbamoyl]ethyl]sulfanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C25H40N2O6S (496.2607)

Leukotriene D4 (LTD4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. LTD4 is a pro-inflammatory mediator known to mediate its effects through specific cell-surface receptors belonging to the G-protein-coupled receptor family, namely the high-affinity CysLT1 (cysteinyl leukotriene 1) receptor. LTD4 is present at high levels in many inflammatory conditions, and areas of chronic inflammation have an increased risk for subsequent cancer development. LTD4 is associated with the pathogenesis of several inflammatory disorders, such as asthma and inflammatory bowel disease. Exposure to LTD4 increases survival and proliferation in intestinal epithelial cells. CysLT1 regulator is up-regulated in colon cancer tissue and LTD4 signalling facilitates the survival of cancer cells. LTD4 could reduce apoptosis in non-transformed epithelial cells. LTD4 causes up-regulation of beta-catenin through the CysLT1 receptor, PI3K (phosphoinositide 3-kinase), and GSK-3β (glycogen synthase kinase 3β). LTD4 induces beta-catenin translocation to the nucleus and activation of TCF/LEF family of transcription factors. LTD4 causes accumulation of free beta-catenin in non-transformed intestinal epithelial cells through the CysLT1 receptor, and this accumulation is dependent upon the activation of PI3K as well as GSK-3β inactivation (PMID: 16042577, 12607939). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent and are able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis through receptor-mediated G-protein linked signaling pathways. Leukotriene D4 (LTD4) is a cysteinyl leukotriene a family of potent inflammatory mediators. LTD4 is a pro-inflammatory mediator known to mediate its effects through specific cell-surface receptors belonging to the G-protein-coupled receptor family, namely the high-affinity CysLT1 (cysteinyl leukotriene 1) receptor. LTD4 is present at high levels in many inflammatory conditions, and areas of chronic inflammation have an increased risk for subsequent cancer development; LTD4 is associated with the pathogenesis of several inflammatory disorders, such as asthma and inflammatory bowel disease. Exposure to LTD4 increases survival and proliferation in intestinal epithelial cells. CysLT1 regulator is up-regulated in colon cancer tissue and LTD4 signalling facilitates the survival of cancer cells. LTD4 could reduce apoptosis in non-transformed epithelial cells. LTD4 causes up-regulation of b-catenin through the CysLT1 receptor, PI3K (phosphoinositide 3-kinase) and GSK-3b (glycogen synthase kinase 3b). LTD4 induces b-catenin translocation to the nucleus and activation of TCF/LEF family of transcription factors. LTD4 causes accumulation of free b-catenin in non-transformed intestinal epithelial cells through the CysLT1 receptor, and this accumulation is dependent upon the activation of PI3K as well as GSK-3b inactivation. (PMID: 16042577, 12607939)

N3-Acetylgentamicin

C19H36N4O11 (496.238)

6-[2-Amino-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid

6-({2-amino-2-[(carboxymethyl)-C-hydroxycarbonimidoyl]ethyl}sulphanyl)-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C25H40N2O6S (496.2607)

6alpha-19-[3-(4-Hydroxyphenyl)propanoyl] ester:6,19-Dihydroxy-3-oxo-5(10),13-halimadien-15,16-olide

C29H36O7 (496.2461)

Wittifuran C

C29H36O7 (496.2461)

3-N-Acetylribostamycin

C19H36N4O11 (496.238)

C31H32N2O4

C31H32N2O4 (496.2362)

Uliginosin B

C29H36O7 (496.2461)

15-O-acetyl-5beta-hydroxyisocharaciol-3-benzoate

C29H36O7 (496.2461)

1-O-decanoyl-6-O-D-beta-glucopyranosyl-beta-D-glucopyranose|6-O-(beta-D-glucopyranosyl)-1-O-decanoyl-beta-D-glucopyranose|nonioside R

C22H40O12 (496.252)

munronoid B

C29H36O7 (496.2461)

15-O-acetyl-3-O-benzoylcharaciol-5beta,6beta-oxide

C29H36O7 (496.2461)

21,25,26,27-tetranorapoeupha-6alpha-methoxy-7alpha-acetoxy-2,14,20(22)-trien-1,12,16,23-tetraone|21,25,26,27-tetranorapotirucalla-6alpha-methoxy-7alpha-acetoxy-2,14,20(22)-trien-1,12,16,23-tetraone|meliatetraone

21,25,26,27-tetranorapoeupha-6alpha-methoxy-7alpha-acetoxy-2,14,20(22)-trien-1,12,16,23-tetraone|21,25,26,27-tetranorapotirucalla-6alpha-methoxy-7alpha-acetoxy-2,14,20(22)-trien-1,12,16,23-tetraone|meliatetraone

C29H36O7 (496.2461)

Sentamicin A(y)

C19H36N4O11 (496.238)

Euphoscopin L

C29H36O7 (496.2461)

4alpha,6alpha-dihydroxy-A-homoazadiradion

C29H36O7 (496.2461)

macropodumine J|methyl rel-(3R,6R,10aS,11S,12aS)-5-(acetyloxy)-5a-[(acetyloxy)methyl]-12b-cyano-2,3,3a,5,5a,6,7,8,9,10,10a,11,12,12b-tetradecahydro-3-methyl-4H-1,6-methanocyclopenta[1,8]azuleno[4,3a-g]indole-11-carboxylate

macropodumine J|methyl rel-(3R,6R,10aS,11S,12aS)-5-(acetyloxy)-5a-[(acetyloxy)methyl]-12b-cyano-2,3,3a,5,5a,6,7,8,9,10,10a,11,12,12b-tetradecahydro-3-methyl-4H-1,6-methanocyclopenta[1,8]azuleno[4,3a-g]indole-11-carboxylate

C28H36N2O6 (496.2573)

Gentamicin A4

C19H36N4O11 (496.238)

12-deacetoxytoonacilin

C29H36O7 (496.2461)

C30H32N4O3

C30H32N4O3 (496.2474)

macrocarpin C

C29H36O7 (496.2461)

4-decanoylsucrose

C22H40O12 (496.252)

LTD4

C25H40N2O6S (496.2607)

[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl 8-methylnonanoate

NCGC00380959-01![(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl 8-methylnonanoate

C22H40O12 (496.252)

LTD4-[d5]

C25H40N2O6S (496.2607)

CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0222.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0222.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0222.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 40.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 30.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0000153.mzML; PROCESSING averaging of repeated ion fragments at 20.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ]

[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl 8-methylnonanoate [IIN-based on: CCMSLIB00000846747]

NCGC00380959-01![(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl 8-methylnonanoate [IIN-based on: CCMSLIB00000846747]

C22H40O12 (496.252)

[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl 8-methylnonanoate [IIN-based: Match]

NCGC00380959-01![(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl 8-methylnonanoate [IIN-based: Match]

C22H40O12 (496.252)

Ala His Asn Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]-5-carbamimidamidopentanoic acid

C19H32N10O6 (496.2506)

Ala His Arg Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]-3-carbamoylpropanoic acid

C19H32N10O6 (496.2506)

Ala Ile Met Tyr

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-aminopropanamido]-3-methylpentanamido]-4-(methylsulfanyl)butanamido]-3-(4-hydroxyphenyl)propanoic acid